Abstract
Interleukins (ILs) are involved in the occurrence and development of numerous types of cancer, and serve a critical role in the development of effective cancer therapeutics. The aim of the present study was to investigate the effect of IL-27 on chemotherapy resistance in lung cancer cells, and analyze its potential molecular mechanism in lung cancer tissues. Western blot analysis and reverse transcription-quantitative polymerase chain reaction were performed to examine the RNA and protein expression levels of IL-27. A Cell Counting Kit-8 assay was performed to evaluate the proliferation rates of the lung cancer line A549. Flow cytometry was subsequently applied to determine the rate of apoptosis in A549 cells. The data obtained revealed that the expression of IL-27 with cisplatin, significantly suppressed the proliferation and apoptosis of A549 cells compared with that in the cisplatin treatment group alone. The expression of Akt and apoptosis factors such as Caspase-3 and Bcl-2/Bax also ascertained that upregulated IL-27 inhibited the development of cancer and increased apoptosis in the A549 cells. Therefore, IL-27 may represent a potential target for antitumor therapy, especially when considering the clinical challenges presented by the development of chemoresistance in tumors. These findings suggest that IL-27 is a promising biomarker and represents a novel treatment strategy for patients with lung cancer.
Introduction
Lung cancer remains the leading cause of cancer-related mortality worldwide. While cisplatin is a foundational chemotherapeutic agent for lung adenocarcinoma, its clinical utility is often limited by the emergence of chemoresistance. This resistance typically involves the overactivation of survival pathways and the evasion of programmed cell death (apoptosis). Interleukin-27 (IL-27), a member of the IL-12 cytokine family, has demonstrated significant anti-tumor properties in various malignancies. This study investigates whether IL-27 expression correlates with clinical outcomes in lung cancer and explores its potential to sensitize cancer cells to cisplatin-based therapy by modulating key survival signaling pathways.
Methods
This research combined clinical tissue analysis with in vitro experimental models. A total of 30 lung cancer tissues and 30 adjacent normal tissues were collected from patients at Suizhou Central Hospital. IL-27 expression levels were quantified using RT-qPCR for mRNA and Western blotting for protein analysis.
For functional studies, the A549 lung adenocarcinoma cell line was utilized. Cells were divided into three groups: control (Blank), cisplatin-only, and a combination of cisplatin and IL-27. Cell proliferation and viability were assessed using the CCK-8 assay over a 48-hour period. Apoptosis rates were determined via flow cytometry using Annexin V/FITC staining. Finally, the molecular mechanism was explored by analyzing the expression of the Akt signaling pathway and apoptotic markers (Bax, Bcl-2, and Caspase-3) through Western blotting.
Results
Clinical Downregulation of IL-27
Analysis of clinical samples revealed that IL-27 expression is significantly lower in lung tumor tissues compared to adjacent healthy tissues ($P < 0.01$). Furthermore, lower IL-27 levels were strongly associated with poor tumor differentiation and the presence of lymphatic metastasis ($P < 0.001$), suggesting that IL-27 may function as an anti-oncogene in lung cancer progression.
Enhancement of Chemosensitivity
In vitro experiments demonstrated that while cisplatin alone inhibits A549 cell growth, the addition of IL-27 significantly enhances this inhibitory effect. The combination group showed the lowest cell viability across all time points ($P < 0.05$), indicating a synergistic effect between IL-27 and cisplatin.
Molecular Mechanism: The Akt Pathway
The study identified the inhibition of the Akt signaling pathway as the primary mechanism for IL-27-mediated sensitization. IL-27 treatment led to a marked decrease in Akt and anti-apoptotic Bcl-2 protein levels, while increasing the expression of pro-apoptotic factors Bax and Caspase-3. By suppressing Akt, IL-27 effectively lowers the threshold for apoptosis, allowing cisplatin to more efficiently trigger cell death.
Discussion and Conclusion
These findings highlight IL-27 as a potent sensitizer for chemotherapy in lung cancer. By acting as an "off-switch" for the Akt survival pathway, IL-27 overcomes the biological shields that cancer cells use to resist cisplatin. Although this study is limited by a relatively small clinical sample size and the use of a single cell line, it provides a strong foundation for further investigation. Future research should focus on validating these results in larger multi-center cohorts and in vivo xenograft models. Ultimately, IL-27 represents both a promising diagnostic biomarker and a potential therapeutic partner to improve outcomes for patients facing chemoresistant lung cancer.
Summary updated